TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17590215

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 311

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 311
Study: 15554753

Group type: EXPERIMENTAL
Intervention: Clodronate (clodronate disodium, Bonefos)
Number of subjects: 0
Study: 11881575

Group type: EXPERIMENTAL
Intervention: Yoga training for 1 hour 15 minutes per day, 7 days a week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Physical training for 1 hour 15 minutes per day, 7 days a week
Number of subjects: 20
Study: 9693934

Group type: EXPERIMENTAL
Intervention: Metformin (M; n = 15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (P; n = 15)
Number of subjects: 30
Study: 7835855

Group type: EXPERIMENTAL
Intervention: Capitated funding program
Number of subjects: 422

Group type: COMPARATOR
Intervention: Standard fee‐based services (Control)
Number of subjects: 422
Study: 17171863

Group type: EXPERIMENTAL
Intervention: Propofol, 2.5 mg/kg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Thiamylal, 4 mg/kg
Number of subjects: 16
Study: 29575668

Group type: EXPERIMENTAL
Intervention: Educational intervention (simple advice)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Not applicable (control group dropped out)
Number of subjects: 130
Study: 28963127

Group type: EXPERIMENTAL
Intervention: Light resistance exercise (30% 1RM)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Heavy resistance exercise (80% 1RM)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Light resistance exercise (30% 1RM) and Heavy resistance exercise (80% 1RM)
Number of subjects: 15
Study: 26223978

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise for 24 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no regular exercise)
Number of subjects: 43
Study: 23030403

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 7774

Group type: COMPARATOR
Intervention: Placebo-controlled
Number of subjects: 7774

Group type: COMPARATOR
Intervention: Active-comparator
Number of subjects: 7774

Group type: COMPARATOR
Intervention: Placebo-controlled crossover
Number of subjects: 7774
Study: 22027664

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) administered in doses from 2250 to 3000 mg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 18453933

Group type: EXPERIMENTAL
Intervention: Nonfaculty registered nurses supervising high-fidelity human-patient simulation
Number of subjects: 0
Study: 16532095

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg of elemental zinc/cap/day) for 3 months
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 101
Study: 15231905

Group type: EXPERIMENTAL
Intervention: Tonsillectomy and Adenoidectomy (T&A)
Number of subjects: 59

Group type: COMPARATOR
Intervention: No surgery (observation)
Number of subjects: 59
Study: 11361230

Group type: EXPERIMENTAL
Intervention: Absorbitol (250 mg) 3 times a day before meals
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 9231150

Group type: EXPERIMENTAL
Intervention: Generating information
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reading information
Number of subjects: 0
Study: 7970073

Group type: EXPERIMENTAL
Intervention: Cervical CT infection
Number of subjects: 80

Group type: COMPARATOR
Intervention: Careful screening during pregnancy
Number of subjects: 80
Study: 3310620

Group type: EXPERIMENTAL
Intervention: Hemodialysis without anticoagulation
Number of subjects: 49
Study: 29888613

Group type: EXPERIMENTAL
Intervention: CRD-Pre
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RCT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RDD
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic RDD
Number of subjects: 0
Study: 27367436

Group type: EXPERIMENTAL
Intervention: Very low nicotine cigarettes (VLNCs; 0.4 mg nicotine/g tobacco) for 6 weeks
Number of subjects: 242
Study: 24102480

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 26

Group type: COMPARATOR
Intervention: Acupressure and massage (Control)
Number of subjects: 26
Study: 22082281

Group type: EXPERIMENTAL
Intervention: Freshest available compatible RBCs
Number of subjects: 51
Study: 20847993

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study: 18628485

Group type: EXPERIMENTAL
Intervention: EHCSS (electrically heated cigarette smoking system)
Number of subjects: 18

Group type: COMPARATOR
Intervention: CC (conventional cigarette)
Number of subjects: 18

Group type: COMPARATOR
Intervention: NS (no smoking)
Number of subjects: 18
Study: 16816829

Group type: EXPERIMENTAL
Intervention: Active rTMS (1 Hz at 110% of motor threshold) administered over the left dorso-lateral prefrontal cortex for 10 sessions.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham rTMS administered over the left dorso-lateral prefrontal cortex for 10 sessions.
Number of subjects: 33
Study: 12932382

Group type: EXPERIMENTAL
Intervention: Immediate systemic therapy with oral chlorambucil 10 mg per day continuously
Number of subjects: 309

Group type: COMPARATOR
Intervention: Observation with systemic therapy delayed until disease progression
Number of subjects: 309
Study: 10190655

Group type: EXPERIMENTAL
Intervention: Vapreotide (1.5 mg day(-1) s.c.) for 7 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7674883

Group type: EXPERIMENTAL
Intervention: Mindful exercise (ME) group - Tai Chi type program
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Moderate intensity walking group (MW)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Low intensity walking group (LW)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Low intensity walking plus relaxation response group (LWR)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 135
Study: 2502385

Group type: EXPERIMENTAL
Intervention: Low dose (20 mg/day for adult)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: High dose (80 mg/day for adult)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Low dose (20 mg/day for adult) in patients with Lennox-Gastaut syndrome
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: High dose (80 mg/day for adult) in patients with Lennox-Gastaut syndrome
Number of subjects: 190
Study: 1106806

Group type: EXPERIMENTAL
Intervention: Tension sutures tied loosely (over three fingers of the assistant's hand)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tension sutures tied flush with the wound
Number of subjects: 0
Study: 31916007

Group type: EXPERIMENTAL
Intervention: AYA
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Middle-aged adults
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Middle-aged men
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: AYA men
Number of subjects: 1135
Study: 30763730

Group type: EXPERIMENTAL
Intervention: Osimertinib (80 mg once daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Osimertinib plus Durvalumab (10 mg/kg every 2 weeks)
Number of subjects: 29
Study: 28419124

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once a day
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 26123068

Group type: EXPERIMENTAL
Intervention: ARTEMIS+CM (n = 12)
Number of subjects: 21

Group type: COMPARATOR
Intervention: CM-only (n = 9)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study: 23612408

Group type: EXPERIMENTAL
Intervention: Neyromidin
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 40
Study: 21175914

Group type: EXPERIMENTAL
Intervention: Weight management program
Number of subjects: 0
Study: 19782789

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Number of subjects: 240

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study: 17712202

Group type: EXPERIMENTAL
Intervention: Intra-aortic balloon pump (IABP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No IABP
Number of subjects: 33
Study: 14739127

Group type: EXPERIMENTAL
Intervention: tranexamic acid (2 g, n=8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo (n=8)
Number of subjects: 16
Study: 11434163

Group type: EXPERIMENTAL
Intervention: Platelet activation assessment at the onset of INS and after 2 weeks of therapy
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Expression of CD42b at the onset of INS
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison with healthy children (group B)
Number of subjects: 24
Study: 10050266

Group type: EXPERIMENTAL
Intervention: Low-sucrose diet for one month (50 patients)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Usual diet for one month (55 patients)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Low-sucrose diet (50 patients)
Number of subjects: 107
Study: 8042724

Group type: EXPERIMENTAL
Intervention: Diclofenac (50 mg intramuscularly before surgery, repeated at 4 and 10 hours)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Saline (intramuscularly)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Morphine (10 mg intravenously after assessing block height)
Number of subjects: 26
Study: 3635599

Group type: EXPERIMENTAL
Intervention: Self-selected music as a conditioning aid during prepared childbirth education
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 30
Study: 29572715

Group type: EXPERIMENTAL
Intervention: Non-apical RV leads
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Non-apical RV and apical LV leads
Number of subjects: 743

Group type: COMPARATOR
Intervention: RV-LV lead sub-groups
Number of subjects: 743
Study: 26756859

Group type: EXPERIMENTAL
Intervention: Moderate/severe CAC
Number of subjects: 7492

Group type: COMPARATOR
Intervention: Nil/mild CAC
Number of subjects: 7492
Study: 24983709

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0
Study: 22505276

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20528799

Group type: EXPERIMENTAL
Intervention: Supine position exclusively
Number of subjects: 112

Group type: COMPARATOR
Intervention: Alternated between supine and prone position every third hour
Number of subjects: 112
Study: 18947426

Group type: EXPERIMENTAL
Intervention: Enteral acidic and neutral oligosaccharides supplementation (20%/80%)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo supplementation (maltodextrin)
Number of subjects: 120
Study: 18443928

Group type: EXPERIMENTAL
Intervention: Cefditoren (CDN)
Number of subjects: 1322

Group type: COMPARATOR
Intervention: Control (penicillin V, cefuroxime, or amoxicillin/clavulanate)
Number of subjects: 1322
Study: 15164512

Group type: EXPERIMENTAL
Intervention: Allicor (600 mg daily)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 11171786

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (ramipril 10 mg/d)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Angiotensin II type 1 receptor antagonist (losartan 100 mg/d)
Number of subjects: 35
Study: 9416986

Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg once daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: Atenolol 50 mg once daily
Number of subjects: 30
Study: 7976112

Group type: EXPERIMENTAL
Intervention: Reading
Number of subjects: 16

Group type: COMPARATOR
Intervention: All conditions
Number of subjects: 16

Group type: COMPARATOR
Intervention: TI, TE, VT
Number of subjects: 16
Study: 3089433

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison between Propranolol and Pindolol
Number of subjects: 40
Study: 31071249

Group type: EXPERIMENTAL
Intervention: Combination of 6 strains of probiotics for 3 months
Number of subjects: 34
Study: 27876806

Group type: EXPERIMENTAL
Intervention: 75 mg aspirin (ASA)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Water-soluble tomato extract Fruitflow (FF)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Concomitant FF and ASA
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 47
Study: 25972532

Group type: EXPERIMENTAL
Intervention: 2 portions of FVs daily (160 g)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 4 portions of FVs daily (320 g)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 7 portions of FVs daily (560 g)
Number of subjects: 92
Study: 23525882

Group type: EXPERIMENTAL
Intervention: Device used group (medical ring)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Device not used group (control)
Number of subjects: 37
Study: 21557791

Group type: EXPERIMENTAL
Intervention: IV Valproate (VPA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Continuous Diazepam (DZP)
Number of subjects: 66
Study: 18413175

Group type: EXPERIMENTAL
Intervention: Diet I (low carbohydrate)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Diet II (low fat)
Number of subjects: 118
Study: 17412748

Group type: EXPERIMENTAL
Intervention: Car seat trial
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nurse observations during car seat trial
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cot
Number of subjects: 20

Group type: COMPARATOR
Intervention: Car seat
Number of subjects: 20
Study: 14754791

Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 3886

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3886
Study: 11348708

Group type: EXPERIMENTAL
Intervention: Hepacare (1 month/two dose regimen)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Engerix-B (2 month/three dose regimen)
Number of subjects: 400
Study: 9207585

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intracervical contraceptive device (group 1, n = 151)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing fundal contraceptive device (group 2, n = 147)
Number of subjects: 298
Study: 8424293

Group type: EXPERIMENTAL
Intervention: Prophylactic dixyrazine 0.25 mg kg‐1 i.v. after surgery
Number of subjects: 116

Group type: COMPARATOR
Intervention: No prophylactic dixyrazine
Number of subjects: 116
Study: 3326118

Group type: EXPERIMENTAL
Intervention: 7.5 mg zopiclone
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: 5 mg nitrazepam
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 28913663

Group type: EXPERIMENTAL
Intervention: NBP‐Dads
Number of subjects: 384

Group type: COMPARATOR
Intervention: Active comparison program
Number of subjects: 384
Study: 27141627

Group type: EXPERIMENTAL
Intervention: Scalp acupuncture treatment
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (medication)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Both groups (Scalp acupuncture and Control)
Number of subjects: 61
Study: 24168956

Group type: EXPERIMENTAL
Intervention: Adalimumab plus methotrexate
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Methotrexate-monotherapy
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Adalimumab-continuation
Number of subjects: 1032

Group type: COMPARATOR
Intervention: Placebo plus methotrexate
Number of subjects: 1032

Group type: EXPERIMENTAL
Intervention: Overall adverse events
Number of subjects: 1032
Study: 21442416

Group type: EXPERIMENTAL
Intervention: One interim assessment during a small group work session
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Two interim assessments during a small group work session
Number of subjects: 417

Group type: COMPARATOR
Intervention: Control group receiving no interim assessment
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Interim assessment on tumour pathology
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Interim assessment on topics related to the previous 3 weeks
Number of subjects: 417
Study: 21189212

Group type: EXPERIMENTAL
Intervention: Ankle tape applied for lateral ligament sprain in the non-dominant leg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no ankle tape)
Number of subjects: 40
Study: 18179316

Group type: EXPERIMENTAL
Intervention: Verbalization of thoughts
Number of subjects: 0
Study: 15725113

Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (women not offered screening mammography)
Number of subjects: 0
Study: 11772479

Group type: EXPERIMENTAL
Intervention: Abstinence reinforcement (n=26)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Attendance reinforcement (n=22)
Number of subjects: 48
Study: 10198297

Group type: EXPERIMENTAL
Intervention: Mixed amino acid (MAA) solution (40 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Essential amino acid (EAA) solution (40 g)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo solution (PLA)
Number of subjects: 6
Study: 7775360

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.4 to 1.3 mg/kg per day, mean 0.7 mg/kg per day)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Bupropion (1.4 to 5.7 mg/kg per day, mean 3.3 mg/kg per day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 15
Study: 1692095

Group type: EXPERIMENTAL
Intervention: Radiation therapy alone
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Surgical treatment with radiation
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Combined radiation and chemotherapy
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 140
Study: 498151

Group type: EXPERIMENTAL
Intervention: cis-platinum (100 mg/m2) administered via rapid infusion (15-minute)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cis-platinum (100 mg/m2) administered via 6-hour infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cis-platinum with concomitant administration of mannitol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cis-platinum in patients with renal impairment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cis-platinum
Number of subjects: 0
Study: 31215242

Group type: EXPERIMENTAL
Intervention: Classical oral Navelbine (once weekly)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metronomic Navelbine
Number of subjects: 0
Study: 28366440

Group type: EXPERIMENTAL
Intervention: Progressive learning-based curriculum (PLC)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard comprehensive curriculum (SCC)
Number of subjects: 37
Study: 25481364

Group type: EXPERIMENTAL
Intervention: Bimanual examination and ultrasound
Number of subjects: 0
Study: 23648613

Group type: EXPERIMENTAL
Intervention: Segmental muscle vibration (SMV) combined with general physical therapy
Number of subjects: 44

Group type: COMPARATOR
Intervention: General physical therapy (Control)
Number of subjects: 44
Study: 21177038

Group type: EXPERIMENTAL
Intervention: Standard feed supplemented with 120 ppm of coumestans from Eclipta alba
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Standard feed supplemented with 180 ppm of coumestans from Eclipta alba
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard feed (negative control)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Standard feed supplemented with 66 ppm of salinomycin (positive control)
Number of subjects: 240
Study: 19957513

Group type: EXPERIMENTAL
Intervention: Cognitive impairment group (serum uric acid level: 249 micromol/L ± 59 micromol/L)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Non-cognitive impairment group (serum uric acid level: 323 micromol/L ± 52 micromol/L)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cognitive scores in PD patients
Number of subjects: 104
Study: 17181566

Group type: EXPERIMENTAL
Intervention: Prior gestational diabetes (GD)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal glucose tolerance (control group)
Number of subjects: 48
Study: 15794407

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with Dermatophagoides pteronyssinus (500, 1000, 2000, 5000, 8000, and 10,000 biological units)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with Dermatophagoides pteronyssinus
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 50
Study: 11406860

Group type: EXPERIMENTAL
Intervention: Willow bark extract (240 mg salicin/day)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Willow bark extract
Number of subjects: 78
Study: 9835238

Group type: EXPERIMENTAL
Intervention: Routine involvement of a psychiatrist in the assessment and care of medical in-patients with probable psychiatric disorder
Number of subjects: 218

Group type: COMPARATOR
Intervention: Physicians alone (control group)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Physicians informed of screening results
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Treatments recommended by psychiatrists
Number of subjects: 218
Study: 7851375

Group type: EXPERIMENTAL
Intervention: Hot environment (Ta 36.7 +/‐ 0.2 degree C, rh 46.1 +/‐ 3.2%)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Neutral environment (Ta 19.6 +/‐ 0.3 degree C, rh 50.2 +/‐ 1.4%)
Number of subjects: 6
Study: 2670536

Group type: EXPERIMENTAL
Intervention: ACC-9653 (phenytoin prodrug) intravenous administration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACC-9653 (phenytoin prodrug) intramuscular administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium phenytoin intravenous administration
Number of subjects: 0
Study: 412590

Group type: EXPERIMENTAL
Intervention: 400 rads of megavoltage irradiation to the site of the lesion given as a single dose and repeated 7 days later
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonirradiated lesions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Irradiated lesions
Number of subjects: 20
Study: 30500603

Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg once weekly
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Mipomersen 70 mg thrice weekly
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 30173291

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted TAP block with 30 ml 0.25% Bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Periportal local anaesthetic infiltration with 15 ml of 0.5% Bupivacaine
Number of subjects: 60
Study: 27094918

Group type: EXPERIMENTAL
Intervention: Chiral bioanalytical method for R‐ibuprofen and S‐ibuprofen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Achiral bioanalytical method
Number of subjects: 0